These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37144597)

  • 21. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Ossenkoppele R; Rabinovici GD; Smith R; Cho H; Schöll M; Strandberg O; Palmqvist S; Mattsson N; Janelidze S; Santillo A; Ohlsson T; Jögi J; Tsai R; La Joie R; Kramer J; Boxer AL; Gorno-Tempini ML; Miller BL; Choi JY; Ryu YH; Lyoo CH; Hansson O
    JAMA; 2018 Sep; 320(11):1151-1162. PubMed ID: 30326496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
    Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
    J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson's disease patients.
    Wu G; Jiang Z; Pu Y; Chen S; Wang T; Wang Y; Xu X; Wang S; Jin M; Yao Y; Liu Y; Ke S; Liu S
    BMC Neurol; 2022 Jan; 22(1):13. PubMed ID: 34996385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition.
    Kunst J; Marecek R; Klobusiakova P; Balazova Z; Anderkova L; Nemcova-Elfmarkova N; Rektorova I
    Brain Topogr; 2019 Jan; 32(1):142-160. PubMed ID: 30206799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia.
    Mosconi L; Andrews RD; Matthews DC
    J Alzheimers Dis; 2013; 35(3):509-24. PubMed ID: 23478305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
    Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
    Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.
    Li TR; Yao YX; Jiang XY; Dong QY; Yu XF; Wang T; Cai YN; Han Y
    Alzheimers Res Ther; 2022 May; 14(1):66. PubMed ID: 35550625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short-Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease (PD).
    Du J; Zhang P; Tan Y; Gao C; Liu J; Huang M; Li H; Shen X; Huang P; Chen S
    Mov Disord; 2024 Aug; 39(8):1397-1402. PubMed ID: 38561921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology.
    Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L
    Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson's disease.
    Huang P; Zhang P; Du J; Gao C; Liu J; Tan Y; Chen S
    NPJ Parkinsons Dis; 2023 Jul; 9(1):115. PubMed ID: 37460569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.